Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 2,264 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 2,264 shares of the firm’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total value of $919,184.00. Following the transaction, the chief executive officer owned 94,662 shares of the company’s stock, valued at $38,432,772. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 28th, Steven Chapman sold 3,430 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $1,462,346.20.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The shares were sold at an average price of $413.31, for a total transaction of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64.

Natera Price Performance

NTRA stock traded up $11.58 during midday trading on Thursday, hitting $436.00. The stock had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. The business has a fifty day moving average price of $375.27 and a two-hundred day moving average price of $265.54. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period last year, the company posted ($0.74) EPS. On average, analysts expect that Natera, Inc. will post -1.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NTRA shares. Barclays raised their price objective on shares of Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Rothschild & Co Redburn began coverage on shares of Natera in a report on Tuesday, September 8th. They issued a “buy” rating and a $385.00 price target for the company. UBS Group increased their price objective on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. BTIG Research increased their target price on Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Stephens lifted their price objective on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $394.31.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Trading of Natera

Institutional investors and hedge funds have recently made changes to their positions in the company. Greenleaf Trust bought a new stake in Natera in the 3rd quarter worth about $240,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Natera during the 3rd quarter worth approximately $7,545,000. Profund Advisors LLC boosted its stake in shares of Natera by 5.6% in the 3rd quarter. Profund Advisors LLC now owns 6,553 shares of the medical research company’s stock worth $2,708,000 after buying an additional 348 shares during the last quarter. Vise Technologies Inc. boosted its stake in shares of Natera by 5.3% in the 3rd quarter. Vise Technologies Inc. now owns 2,010 shares of the medical research company’s stock worth $831,000 after buying an additional 101 shares during the last quarter. Finally, Americana Partners LLC bought a new position in shares of Natera in the third quarter valued at approximately $203,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.